Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: A pilot study

Journal of Substance Abuse Treatment

Volumn 38, Issue 4, 2010, Pages 408-411

  Oviedo Joekes, Eugenia ^a,b   Guh, Daphne ^b   Brissette, Suzanne ^c   Marsh, David C ^a,b,d,e   Nosyk, Bohdan ^b   Krausz, Michael ^a,b   Anis, Aslam ^a,b   Schechter, Martin T ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d VANCOUVER COASTAL HEALTH   (Canada)

^e UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Diacetylmorphine, Injectable; Double blind; Hydromorphone, Injectable; Opioid dependence; Substitution treatment

Indexed keywords

DIAMORPHINE; HYDROMORPHONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; OPIATE ADDICTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREATMENT DURATION;

ADULT; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HEROIN; HEROIN DEPENDENCE; HUMANS; HYDROMORPHONE; INJECTIONS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77952239642     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.03.003     Document Type: Article

References (23)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders DSM-IV 1994, American Psychiatric Association.
2. Bammer G., Dance P., McDonald D. Report into the feasibility of trialling hydromorphone as a treatment for heroin dependence in the Australian Capital Territory 2004, Australian National University.
3. Brands B., Marsh D., Busto U., Macdonald A. Comparison of heroin and hydromorphone in opioid users. Clinical Pharmacology & Therapeutics 2004, 75:P3.
4. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug & Alcohol Dependence 2009, 105:9-15.
5. Gowing L., Farrell M., Bornemann R., Sullivan L., Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database System Review 2008, 2:CD004145.
6. Greenwald M.K., Hursh S.R. Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of unit price and pre-session drug supply. Drug & Alcohol Dependence 2006, 85:35-48.
7. Haasen C., Verthein U., Degkwitz P., Berger J., Krausz M., Naber D. Heroin-assisted treatment for opioid dependence: Randomised controlled trial. British Journal of Psychiatry 2007, 191:55-62.
8. Hall W.D., Kimber J., Mattick R.P. Breaking the deadlock over an Australian trial of injectable opioid maintenance. Medical Journal of Australia 2002, 176:72-73.
9. Health Canada Best practices in methadone maintenance treatment 2002, Minister of Public Works and Government Services Canada, Ontario, Canada.
10. ICH Harmonised Tripartite Guideline Guideline for good clinical practice. EMEA 2002.
11. Kokkevi A., Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. European Addiction Research 1995, 1:208-210.
12. March J.C., Oviedo-Joekes E., Perea-Milla E., Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. Journal of Substance Abuse Treatment 2006, 31:203-211.
13. Oviedo-Joekes E., Brissette S., Marsh D.C., Lauzon P., Guh D., Anis A., et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine 2009, 361:777-786.
14. Oviedo-Joekes E., Nosyk B., Brissette S., Chettiar J., Schneeberger P., Marsh D.C., et al. The North American Opiate Medication Initiative (NAOMI): Profile of participants in North America's First Trial of Heroin-Assisted Treatment. Journal of Urban Health 2008, 85:812-825.
15. Oviedo-Joekes E., Nosyk B., Marsh D., Guh D., Brissette S., Gartry C., et al. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI Study. Clinical Trials 2009, 6:261-271.
16. Pharmascience Inc Hydromorphone, product monograph 1996.
17. Preston K.L., Bigelow G.E. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. Journal of Pharmacology and Experimental Therapy 2000, 295:114-124.
18. Quigley C., Wiffen P. A systematic review of hydromorphone in acute and chronic pain. Journal of Pain Symptom Management 2003, 25:169-178.
19. Rehm J., Gschwend P., Steffen T., Gutzwiller F., Dobler-Mikola A., Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001, 358:1417-1423.
20. Sacerdote P., Franchi S., Gerra G., Leccese V., Panerai A.E., Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behavior & Immunity 2008, 22:606-613.
21. Strain E.C., Walsh S.L., Bigelow G.E. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl) 2002, 159:161-166.
22. van den Brink W., Hendriks V.M., Blanken P., Koeter M.W., van Zwieten B.J., van Ree J.M. Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. British Medical Journal 2003, 327:310.
23. Wallenstein S.L., Houde R.W., Portenoy R., Lapin J., Rogers A., Foley K.M. Clinical analgesic assay of repeated and single doses of heroin and hydromorphone. Pain 1990, 41:5-13.